intraflagellar transport 22Genealiases: CFAP9 · FAP9 · RABL5
Q-omics provides the consensus-scored IFT22 profile across patient tissues and cancer cell-line models. IFT22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IFT22 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, IFT22 protein abundance shows 22,485 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, COAD, and PDAC as cancer lineages where IFT22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFT22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFT22 survival associations across molecular data types. IFT22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFT22 RNA expression–survival associations across cancer types. High IFT22 expression shows unfavorable associations in KICH, LGG, LIHC, LUSC and ACC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IFT22 RNA expression.
This table summarizes IFT22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IFT22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFT22 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, HNSC, KIRP and BRCA. The COAD box plot shows higher IFT22 RNA expression in tumor versus normal tissue (log2 FC = +1.303, t-test p < 0.001).
This table shows molecular features associated with IFT22 in patient tissues and cancer cell lines. In patient samples, IFT22 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFT22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
